 "Wockhardt falls over 5% as US unit gets FDA warning letter")
Wockhardt dipped nearly 7% to Rs 701 on the BSE in early morning trade after the pharmaceutical company said that its step-down unit in the US, Morton Grove Pharmaceuticals Inc., has received a warning letter from the US Food and Drug Administration (FDA).
“US Food and Drug Administration ('USFDA') has issued a warning letter to Morton Grove Pharmaceuticals Inc., USA, a step-down subsidiary of the company,” Wockhardt said in a regulatory filing.
This would mean that current portfolio of the Company will continue to be made available in the market. However, new approvals will be withheld till resolution, it added.
Wockhardt said the company, with the help of the consultants, has already initiated appropriate measures since last several months to address the issues raised by USFDA.
The stock had outperformed the market in past two weeks, surged 14% as compared to 3% rise in the S&P BSE Sensex till Wednesday.
At 9:25 am; the stock was down 5% at Rs 716 against 0.34% rise in the benchmark index. A combined 1.72 million shares changed hands on the counter on the BSE and NSE so far.
“US Food and Drug Administration ('USFDA') has issued a warning letter to Morton Grove Pharmaceuticals Inc., USA, a step-down subsidiary of the company,” Wockhardt said in a regulatory filing.
This would mean that current portfolio of the Company will continue to be made available in the market. However, new approvals will be withheld till resolution, it added.
Wockhardt said the company, with the help of the consultants, has already initiated appropriate measures since last several months to address the issues raised by USFDA.
The stock had outperformed the market in past two weeks, surged 14% as compared to 3% rise in the S&P BSE Sensex till Wednesday.
At 9:25 am; the stock was down 5% at Rs 716 against 0.34% rise in the benchmark index. A combined 1.72 million shares changed hands on the counter on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%